Physician profile
Daniel Pluznik
NPI 1699871194
$6,150.21
in general payments reported to CMS, 2019-2025
30 companies · $898 in 2025
The $898 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $404 · 2021: $597 · 2022: $1,271 · 2023: $1,004 · 2024: $1,067 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $1,017.06 | 2021-2023 | |
| Abbvie INC. | $681.96 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $608.53 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Allergan, INC. | $451.91 | 2019-2021 | |
| Alcon Vision LLC | $409.93 | 2019-2025 | Clareon, Eysuvis, Clareon Panoptix Pro |
| Biotissue Holdings INC. | $369.97 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $362.76 | 2024-2025 | Xdemvy |
| Heru, INC. | $339.75 | 2022 | |
| Novartis Pharmaceuticals Corporation | $309.63 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $285.94 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $192.67 | 2019-2021 | |
| Shire North American Group INC | $140.08 | 2019 | |
| Aerie Pharmaceuticals, INC. | $138.13 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $136.77 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $118.80 | 2023 | Syfovre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $110.93 | 2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.85 | 2019-2021 | |
| Dompe US, INC. | $56.08 | 2022-2025 | Oxervate |
| Glaukos Corporation | $55.38 | 2024 | Idose |
| Rxsight INC | $53.80 | 2022 | |
| Harrow Eye, LLC | $38.36 | 2025 | Vevye |
| Sight Sciences, INC. | $37.53 | 2023 | Sion Surgical Instrument, Omni Surgical System |
| Oyster Point Pharma, INC. | $25.59 | 2023 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $24.93 | 2019 | |
| Tearlab Corp | $24.81 | 2022 | |
| Mallinckrodt Hospital Products INC. | $24.75 | 2021 | |
| Thea Pharma INC. | $24.48 | 2024 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Omeros Corporation | $14.68 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pluznik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.